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Abstract 
Case report on a case of sole i(4)(p10) in 
myelodysplastic syndrome. 
Clinics 
Age and sex 
79 years old male patient. 
Previous history 
No preleukemia, previous malignancy (the patient had 
an acute myeloid leukemia (AML) of unknown type, 
20 years ago), no inborn condition of note. 
Organomegaly 
No hepatomegaly, no splenomegaly, no enlarged lymph 
nodes, no central nervous system involvement.  
Blood 
WBC: 2.7 X 109/l 
HB: 9.7g/dl 
Platelets: 73 X 109/l 
Blasts: 0% 
Bone marrow: Hypercellullar, multilineage dysplasia: 
13% blasts, no Auer rods, 12% ring sideroblasts, 4% 
basophils. 
Cyto-Pathology 
Classification 
Cytology 
Refractory anemia with excess blasts (RAEB) 
Diagnosis 
RAEB2 (WHO 2008) 
Survival 
Date of diagnosis: 01-2013 
Treatment: Azacytidine. Blood transfusions were no 
more needed since. 
Complete remission: no  
Treatment related death: no  
Relapse: no  
Status: Alive 
Survival: 4 months 
Karyotype 
Sample: Bone marrow 
Culture time: 24h 
Banding: BHG 
Results 
47,XY,+i(4)(p10).ish i(4)(p10)(FRGFR3++, 
wcp4+)[12] / 47,XY,+8[1] 
Other molecular cytogenetics technics 
FISH. probe cytocell: FGFR3/IGH; ERG1; 
RELN/TES; ETO/AML1 (RUNX1T1/RUNX1). probe 
Q-Biogene: wcp4. 
Other molecular cytogenetics results 
nuc ish 5p15(D5S721,D5S23x2)5q31(ERG1x2)[100] ; 
nuc ish 7q22(RELNx2)7q31(TESx2)[100] ; nuc ish 
8q22(RUNX1T1x2),21q22(RUNX1x2)[100] ; nuc ish 
4p16(FGFR3x4),14q32(IGHx2)[40/50] ; ish 
+i(4)4p16(wcp4+,FGFR3++)[3/3] 
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Comments 
We present a new case of isochromosome 4p in a 
myeloid proliferation. The patient, a 79 years old man 
developed an MDS (RAEB2), occurring 20 years after 
an acute myeloid leukemia not otherwise documented. 
Cytogenetics on bone marrow aspirate revealed a 
unique abnormality in the karyotype, an additional 
isochromosome 4p. FISH with wpc4 and FGFR3 
probes confirmed the i(4p) as an extra chromosome. 
The most frequent molecular/cytogenetic abnormalities 
in myeloid proliferations were absent: 5q31, 7q22-q31 
probes (for del 5q or del 7q) and ETO + AML1 probes 
(for +8 or +21) showed no abnormality. 
To our knowledge, this is the sixth reported case of 
myeloid proliferation with an isochromosome 4p as the 
sole karyotype abnormality. The previous published 
cases were M4-AML (3 cases), M2-AML (1 case) and 
RAEB-T (1 case) (Hagemeijer et al., 1981; Hoo et al., 
1995; Chen et al., 1999; Soriani et al., 2010). In this 
short series, only one relapse is recorded after 9 
months, it is the unique case of double i(4p); two cases 
are noted as being in complete remission and two are 
not documented. The present case is not relevant to the 
prognosis value of this karyotype anomaly: first, to date 
the duration of treatment is only three months, but also 
the age of the patient, and a previous history of AML 
are factors which impact the prognosis too greatly by 
themselves. Isochromosome 4p currently does not have 
a specific prognostic value in myeloid proliferations. 
At the present time, what interpretation of i(4)(p10) can 
be proposed? "Considering that trisomy 4 as the sole 
abnormality of karyotype is common anomalies in 
AML and MDS", Chen et al. (1999) suppose that 
"amplification of genes on 4p but not on 4q may play a 
crucial role in the pathogenesis of MDS and AML". 
Recently, two genes located on chromosome 4 were 
identified as playing a role in myeloid proliferations. In 
2003, Dvorak et al. have described the increased 
expression of FGFR3 (4p16), a member of the family 
of tyrosine kinase genes, in myeloid proliferating cells 
of CML and AML. Furthermore TET2 in 4q24 is a 
putative tumor suppressor in myeloid proliferations 
(Delhommeau et al., 2009; Jankowska et al., 2009, 
Vainchenker et al., 2011). Thus it can be assumed that 
the presence of a supernumerary isochromosome 4p 
can increase the expression of FGFR3 in 4p16 without 
increasing the copy number of the tumor suppressor 
gene TET2 in 4q24. 
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Figure 1: RHG; partial panel of chromosomes 4 and i(4)(p10). 
 
Figure 2: one metaphase labelled by wcp4: two normal chromosomes 4 and one extra derived chromosome 4. 
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Figure 3: nuc ish(FGFR3x4,IGHx2); FGFR3 red and IGH green. 
 
 
 
Figure 4: two normal chromosomes 4 labelled by an FGFR3 red probe, one extra chromosome labelled by an FGFR3 red probes and two 
normal chromosomes 14 labelled by an IGH green probe. 
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